Targeting mutant p53 for cancer therapy: direct and indirect strategies
J Hu, J Cao, W Topatana, S Juengpanich, S Li… - Journal of hematology & …, 2021 - Springer
TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …
Molecularly targeted therapies for p53-mutant cancers
D Zhao, WM Tahaney, A Mazumdar, MI Savage… - Cellular and molecular …, 2017 - Springer
The tumor suppressor p53 is lost or mutated in approximately half of human cancers. Mutant
p53 not only loses its anti-tumor transcriptional activity, but also often acquires oncogenic …
p53 not only loses its anti-tumor transcriptional activity, but also often acquires oncogenic …
Targeting mutant p53 for efficient cancer therapy
VJN Bykov, SE Eriksson, J Bianchi… - Nature Reviews Cancer, 2018 - nature.com
The tumour suppressor gene TP53 is the most frequently mutated gene in cancer. Wild-type
p53 can suppress tumour development by multiple pathways. However, mutation of TP53 …
p53 can suppress tumour development by multiple pathways. However, mutation of TP53 …
Advanced strategies for therapeutic targeting of wild-type and mutant p53 in cancer
TP53 is a tumor suppressor gene that encodes a sequence-specific DNA-binding
transcription factor activated by stressful stimuli; it upregulates target genes involved in …
transcription factor activated by stressful stimuli; it upregulates target genes involved in …
Targeting oncogenic mutant p53 for cancer therapy
A Parrales, T Iwakuma - Frontiers in oncology, 2015 - frontiersin.org
Among genetic alterations in human cancers, mutations in the tumor suppressor p53 gene
are the most common, occurring in over 50% of human cancers. The majority of p53 …
are the most common, occurring in over 50% of human cancers. The majority of p53 …
Drugs targeting p53 mutations with FDA approval and in clinical trials
S Nishikawa, T Iwakuma - Cancers, 2023 - mdpi.com
Simple Summary Mutations in the tumor suppressor p53 (p53) occur in~ 50% of human
cancers, the majority of which are missense mutations. Mutations in p53 not only impair the …
cancers, the majority of which are missense mutations. Mutations in p53 not only impair the …
Drugging p53 in cancer: one protein, many targets
Mutations in the TP53 tumour suppressor gene are very frequent in cancer, and attempts to
restore the functionality of p53 in tumours as a therapeutic strategy began decades ago …
restore the functionality of p53 in tumours as a therapeutic strategy began decades ago …
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
K Sabapathy, DP Lane - Nature reviews Clinical oncology, 2018 - nature.com
TP53, which encodes the tumour-suppressor protein p53, is the most frequently mutated
gene across all cancer types. The presence of mutant p53 predisposes to cancer …
gene across all cancer types. The presence of mutant p53 predisposes to cancer …
Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities
p53 is one of the most important tumor suppressor genes that is frequently mutated in
human cancers. Generally, p53 functions as a transcription factor that is stabilized and …
human cancers. Generally, p53 functions as a transcription factor that is stabilized and …